Cited by 1,487Menopause: Health Impacts and TreatmentsEstrogen and related hormone effectsCancer Risks and Factors

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.

Open access

Colditz, Graham A., Hankinson, Susan E., Hunter, David J., Willett, Walter C., Manson, JoAnn E., Stampfer, Meir J., Hennekens, Charles, Rosner, Bernard, Speizer, Frank E.·1995·New England Journal of Medicine

DOI 10.1056/nejm199506153322401

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The effect of adding progestins to estrogen therapy on the risk of breast cancer in postmenopausal women is controversial. METHODS: To quantify the relation between the use of hormones and the risk of breast cancer in postmenopausal women, we extended our follow-up of the participants in the Nurses' Health Study to 1992. The women were asked to complete questionnaires every two years to update information on their menopausal status, use of estrogen and progestin preparations, and any diagnosis of breast cancer. During 725,550 person-years of follow-up, we documented 1935 cases of newly diagnosed invasive breast cancer. RESULTS: The risk of breast cancer was significantly increased among women who were currently using estrogen alone (relative risk, 1.32; 95 percent confidence interval, 1.14 to 1.54) or estrogen plus progestin (relative risk, 1.41; 95 percent confidence interval, 1.15 to 1.74), as compared with postmenopausal women who had never used hormones. Women currently taking hormones who had used such therapy for 5 to 9 years had an adjusted relative risk of breast cancer of 1.46 (95 percent confidence interval, 1.22 to 1.74), as did those currently using hormones who had done so for a total of 10 or more years (relative risk, 1.46; 95 percent confidence interval, 1.20 to 1.76). The increased risk of breast cancer associated with five or more years of postmenopausal hormone therapy was greater among older women (relative risk for women 60 to 64 years old, 1.71; 95 percent confidence interval, 1.34 to 2.18). The relative risk of death due to breast cancer was 1.45 (95 percent confidence interval, 1.01 to 2.09) among women who had taken estrogen for five or more years. CONCLUSIONS: The addition of progestins to estrogen therapy does not reduce the risk of breast cancer among postmenopausal women. The substantial increase in the risk of breast cancer among older women who take hormones suggests that the trade-offs between risks and benefits should be carefully assessed.

Integrity signals

Registry

Crossref · 10.1056/nejm199506153322401

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Variations in mortality by weight among 750,000 men and women
Lew, E. A., & Garfinkel, L. (1979) · Journal of Chronic Diseases · doi:10.1016/0021-9681(79)90119-x · Cited by 1,169
Estrogens, Progestogens, Normal Breast Cell Proliferation, and Breast Cancer Risk
Pike, M. C., SPICER, D. V., Dahmoush, L., & Press, M. F. (1993) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036102 · Cited by 1,009
TEST OF THE NATIONAL DEATH INDEX
Stampfer, M. J., Willett, W. C., Speizer, F. E., DYSERT, D. C., LIPNICK, R. J., ROSNER, B. A., & Hennekens, C. H. (1984) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113804 · Cited by 791
The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer
Key, T. J., & Pike, M. C. (1988) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(88)90173-3 · Cited by 658
The Risk of Breast Cancer after Estrogen and Estrogen–Progestin Replacement
Bergkvist, L., Adami, H., Persson, I. R., Hoover, R. N., & Schairer, C. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908033210505 · Cited by 612
The Effect of Postmenopausal Estrogen Therapy on Bone Density in Elderly Women
Felson, D. T., Zhang, Y., Hannan, M. T., Kiel, D. P., Wilson, P. W. F., & Anderson, J. J. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310143291601 · Cited by 580
THE EPIDEMIOLOGY OF SERUM SEX HORMONES IN POSTMENOPAUSAL WOMEN
Cauley, J. A., Gutai, J. P., Kuller, L. H., LEDONNE, D., & POWELL, J. G. (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115234 · Cited by 485
Biologic Effects of Transdermal Estradiol
Chetkowski, R. J., Meldrum, D. R., Steingold, K. A., Randle, D., Lu, J. K., Eggena, P., Hershman, J. M., Alkjaersig, N. K., Fletcher, A. P., & Judd, H. L. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142505 · Cited by 482
Biologic effects of transdermal estradiol
Chetkowski, R. J., Meldrum, D., & Ka, S. (1987) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(87)90325-0 · Cited by 467

Show all 32 references

Research works printed but not linked: 4

Feinleib M, 1968, J Natl Cancer Inst, 41, 315
Committee on the relationship Between Oral Contraceptives and Breast Cancer, Institute of Medicine. Oral contraceptives & breast cancer. Washington, D.C.: National Academy Press, 1991.
Gambrell RD, 1983, Obstet Gynecol, 62, 435
Rose DP, 1977, Obstet Gynecol, 49, 80

Sorted by citations

Items 601–700 of 999

Balance of Beneficial and Deleterious Health Effects of Quinones: A Case Study of the Chemical Properties of Genistein and Estrone Quinones
Zhang, Q., Tu, T., d’Avignon, D. A., & Gross, M. L. (2008) · Journal of the American Chemical Society · doi:10.1021/ja806478b · Cited by 24
Divergent mechanisms for trophic actions of estrogens in the brain and peripheral tissues
Walf, A. A., Paris, J. J., Rhodes, M. E., Simpkins, J. W., & Frye, C. A. (2010) · Brain Research · doi:10.1016/j.brainres.2010.11.081 · Cited by 26
“The effects of HRT to increase the risk of breast cancer to postmenopausal women are also well understood (Colditz et al., 1995; Magnusson et al., 1999).”
Background
Representations of Menopause and Their Health Care Implications: A Qualitative Study
Jones, J. B. (1997) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(18)30226-5 · Cited by 24
Current breast cancer risks of hormone replacement therapy in postmenopausal women
Shah, N. R., & Wong, T. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.18.2455 · Cited by 24
“Some large observational studies, such as the Collaborative, the Million Women Study and the Nurses’ Health Study, showed increased risk with unopposed estrogen use [12,14,42].”
BackgroundInfluential
Incidence and causes for failure of treatment of women with proven osteoporosis
Zafran, N., Liss, Z., Peled, R., Sherf, M., & Reuveni, H. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1838-z · Cited by 24
“It is known that physicians’ recommendations and explanations affect compliance [40].”
Background
The Safety of Postmenopausal Testosterone Therapy
Maclaran, K., & Panay, N. (2012) · Women s Health · doi:10.2217/whe.12.11 · Cited by 23
“There has been a suggestion from one study that the risk of breast cancer may increase with duration of testosterone treatment [113].”
Background
Soybean Isoflavones as an Alternative to Traditional Hormone Replacement Therapy: Are We There Yet?
Burke, G. L., Vitolins, M. Z., & Bland, D. R. (2000) · Journal of Nutrition · doi:10.1093/jn/130.3.664s · Cited by 25
Medical Management of Osteoporosis
Brunelli, M. P., & Einhorn, T. A. (1998) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-199803000-00005 · Cited by 24
Evaluation of genotoxic potential of synthetic progestins-norethindrone and norgestrel in human lymphocytes in vitro
Ahmad, M. E., Shadab, G. G. H. A., Azfer, M. A., & Afzal, M. (2001) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/s1383-5718(01)00164-4 · Cited by 24
Women’s Health Care During the Perimenopause
Frackiewicz, E. J., & Cutler, N. R. (2000) · Journal of the American Pharmaceutical Association (1996) · doi:10.1016/s1086-5802(16)31127-5 · Cited by 24
Estrogen Replacement Therapy After Breast Cancer: A 12-Year Follow-Up
Peters, G. N., Fodera, T., Sabol, J. L., Jones, S. E., & Euhus, D. (2001) · Annals of Surgical Oncology · doi:10.1007/s10434-001-0828-4 · Cited by 24
Hormone Replacement Therapy and Breast Cancer
Bergkvist, L., & Persson, I. R. (1996) · Drug Safety · doi:10.2165/00002018-199615050-00006 · Cited by 24
The characteristics of malignant breast tumors in hormone replacement therapy users versus nonusers
Pappo, I., Meirshon, I., Karni, T., Siegelmann-Danielli, N., Stahl-Kent, V., Sandbank, J., Wasserman, I., & Halevy, A. (2004) · Annals of Surgical Oncology · doi:10.1007/bf02524346 · Cited by 24
The contribution of postmenopausal hormone use cessation to the declining incidence of breast cancer
Sprague, B. L., Trentham‐Dietz, A., & Remington, P. (2010) · Cancer Causes & Control · doi:10.1007/s10552-010-9682-7 · Cited by 23
“Risk of breast cancer appears to remain elevated for up to 5 years following cessation [11, 26, 27].”
Background
HRT: Some Unresolved Clinical Issues in Breast Cancer, Endometrial Cancer and Premature Ovarian Insufficiency
Davey, D. A. (2012) · Women s Health · doi:10.2217/whe.12.61 · Cited by 24
“07) in women who had used HRT at any time in the past [11].”
Background
Dihydrotanshinone I targets ESR1 to induce DNA double-strand breaks and proliferation inhibition in hepatocellular carcinoma
Nie, Y., Yan, J., Huang, X., Jiang, T., Zhang, S., & Zhang, G. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155767 · Cited by 23
Selective Estrogen Receptor Modulator Delivery of Quinone Warheads to DNA Triggering Apoptosis in Breast Cancer Cells
Peng, K.-W., Wang, H., Qin, Z., Wijewickrama, G. T., Lü, M., Wang, Z., Bolton, J. L., & Thatcher, G. R. J. (2009) · ACS Chemical Biology · doi:10.1021/cb9001848 · Cited by 23
Endometrial safety assessment of a specific and standardized soy extract according to international guidelines
Palacios, S., Pornel, B., Bergeron, C., Chantre, P., Nogales, F. F., Aubert, L., Vazquez, F., Eden, J., & Marès, P. (2007) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3180590c42 · Cited by 23
“Long-term treatment with EPT may increase the risk of developing breast cancer.(3) Small but statistically significant differences were found between previous EPT users and nonusers for most breast cancer risk factors.”
Background
Postmenopausal Female Hormone Use and Estrogen Receptor–Positive and –Negative Breast Cancer in African American Women
Rosenberg, L. A., Bethea, T. N., Viscidi, E., Hong, C., Troester, M. A., Bandera, E. V., Haiman, C. A., Kolonel, L. N., Olshan, A. F., Ambrosone, C. B., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv361 · Cited by 23
Polymorphic catechol-O-methyltransferase gene, duration of estrogen exposure, and breast cancer risk: A nested case–control study in Taiwan
Lin, W., Chou, Y., Wu, M.-H., Jeng, Y.-L., Huang, H.-B., You, S., Chu, T., Chen, C., & Sun, C. (2005) · Cancer Detection and Prevention · doi:10.1016/j.cdp.2005.07.003 · Cited by 23
NON‐GENOMIC VASCULAR ACTIONS OF FEMALE SEX HORMONES: PHYSIOLOGICAL IMPLICATIONS AND SIGNALLING PATHWAYS
Leung, S. W. S., Teoh, H., Keung, W., & Man, R. Y. (2007) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2007.04686.x · Cited by 23
Management of osteoporosis
Miller, P. D. (1999) · Disease-a-Month · doi:10.1016/s0011-5029(99)90010-x · Cited by 23
Impact of Oestradiol and Progesterone on Antioxidant Activity in Normal Human Breast Epithelial Cells in Culture
Dabrosin, C., Hammar, M. L., & Öllinger, K. M. (1998) · Free Radical Research · doi:10.3109/10715769809069276 · Cited by 23
Therapeutic potential of oestrogen receptor ligands in development for osteoporosis
Cho, C. H., & NUTTALL, M. E. (2001) · Emerging Drugs · doi:10.1517/14728214.6.1.137 · Cited by 23
“Because of the known and suspected risks of oestrogen therapy it has been estimated that in the US < 40% of women on ERT will continue treatment beyond one year [6,7].”
Background
Chapter 19. Estrogen Receptor Modulators: Effects in Non-Traditional Target Tissues
Grese, T. A., & Dodge, J. A. (1996) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60458-3 · Cited by 23
What Would Be the Properties of an Ideal SERM?
Anthony, M., Williams, J. K., & Dunn, B. K. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb04031.x · Cited by 23
A randomised, double-blind trial comparing raloxifene HCl and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life
Voss, S., Quail, D., Dawson, A., Bäckström, T., Águas, F., Erenus, M., Thé, H. S., Bonnar, J., Geyter, C. D., Hunter, M. S., et al. (2002) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2002.01510.x · Cited by 23
HRT and breast cancer risk: a clue for interpreting the available data
Campagnoli, C., Biglia, N., Cantamessa, C., Lesca, L., & Sismondi, P. (1999) · Maturitas · doi:10.1016/s0378-5122(99)00082-1 · Cited by 23
“No substantial differences were shown by the three most important American studies [16–18] (Fig.”
Background
Do Progestogens Reduce The Risk of Breast Cancer? A Review of the Evidence
Wren, B. G., & Eden, J. (1996) · Menopause The Journal of The North American Menopause Society · doi:10.1097/00042192-199603010-00003 · Cited by 23
The "epidemic" of breast cancer in the U.S.--determining the factors.
King, S. E., & Schottenfeld, D. (1996) · PubMed · Cited by 23
Postmenopausal Hormone-Replacement Therapy — Time for a Reappraisal?
Brinton, L. A., & Schairer, C. (1997) · New England Journal of Medicine · doi:10.1056/nejm199706193362509 · Cited by 23
Effects of estrogens and androgens on mitochondria under normal and pathological conditions
Mohajeri, M., Martín-Jiménez, C., Barreto, G. E., & Sahebkar, A. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.03.001 · Cited by 23
Breast cancer risk among women under 55 years of age by joint effects of usage of oral contraceptives and hormone replacement therapy
Brinton, L. A., Brogan, D. R., Coates, R. J., Swanson, C. A., Potischman, N. A., & Stanford, J. L. (2018) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001217 · Cited by 22
Hormone Replacement Therapy
Jones, J. B. (1999) · Social Work in Health Care · doi:10.1300/j010v28n03_06 · Cited by 22
Ménopause et hormonothérapie substitutive
Tellier, P., & Godeau, P. (2000) · La Revue de Médecine Interne · doi:10.1016/s0248-8663(00)88956-0 · Cited by 22
Investigating the role of natural phyto-oestrogens on bone health in postmenopausal women
Valtueña, S., Cashman, K. D., Robins, S. P., Cassidy, A., Kardinaal, A. F. M., & Branca, F. (2003) · British Journal Of Nutrition · doi:10.1079/bjn2002799 · Cited by 22
Equine estrogen metabolite 4-hydroxyequilenin induces anchorage-independent growth of human mammary epithelial MCF-10A cells: differential gene expression
Cuendet, M., Liu, X., Pisha, E., Li, Y., Yao, J., Yu, L., & Bolton, J. L. (2004) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2004.02.005 · Cited by 22
Treatment with Progesterone Analogues Decreases Macrophage Fcγ Receptors Expression
Gomez, F., Ruiz, P., Briceño, F., Lopez, R., & Doña, A. M. (1998) · Clinical Immunology and Immunopathology · doi:10.1006/clin.1998.4602 · Cited by 22
Effect of hormone replacement therapy on growth hormone stimulation in women with premature ovarian failure
Hartmann, B. W., Huber, J. C., Kirchengast, S., Söregi, G., & Albrecht, A. E. (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)81483-5 · Cited by 22
Breast cancer risk in postmenopausal women using testosterone in combination with hormone replacement therapy
Bitzer, J., Kenemans, P., & Mueck, A. O. (2008) · Maturitas · doi:10.1016/j.maturitas.2008.01.005 · Cited by 22
“currently no data available on breast cell proliferation for a longer period of follow-up than 6 months, the authors have previously shown that an increase in breast density associated with increased cell proliferation, is fully established during the first few months and will not increase further during prolonged tre…”
Relative Versus Attributable Risk of Breast Cancer from Estrogen Replacement Therapy
Santen, R. J., & Petroni, G. R. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.6.1875 · Cited by 22
Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities
Labrie, F., Labrie, C., BÉLANGER, A., Giguère, V., Simard, J., Mérand, Y., Gauthier, S., Luu-The, V., Candas, B., Martel, C., et al. (2001) · Advances in protein chemistry · doi:10.1016/s0065-3233(01)56009-x · Cited by 22
Reaction of the Premarin Metabolite 4-Hydroxyequilenin Semiquinone Radical with 2‘-Deoxyguanosine: Formation of Unusual Cyclic Adducts
Shen, L., Qiu, S., van Breemen, R. B., Zhang, F., Chen, Y., & Bolton, J. L. (1997) · Journal of the American Chemical Society · doi:10.1021/ja971396q · Cited by 22
Tyrosine kinase inhibitors as antiproliferative agents against an estrogen-dependent breast cancer cell line in vitro
TWADDLE, G. M., Turbov, J. M., Liu, N., & Murthy, S. M. (1999) · Journal of Surgical Oncology · doi:10.1002/(sici)1096-9098(199902)70:2 · Cited by 22
Mammographic changes in women on hormonal replacement therapy
Erel, C. T., Seyisoğlu, H., Şentürk, M. L., Akman, C., Ersavaşti, G., Benian, A., Uras, C., Altuğ, A., & Ertüngealp, E. (1996) · Maturitas · doi:10.1016/0378-5122(96)01034-1 · Cited by 22
Raloxifene Versus Continuous Combined Estrogen/Progestin Therapy: Densitometric and Biochemical Effects in Healthy Postmenopausal Taiwanese Women
Tsai, K., Yen, M., Pan, H., Wu, M., Cheng, W., Hsu, S. H.-J., Yen, B. L., & Huang, K. E. (2001) · Osteoporosis International · doi:10.1007/s001980170011 · Cited by 22
Hormone replacement therapy again
Khaw, K. (1998) · BMJ · doi:10.1136/bmj.316.7148.1842 · Cited by 22
Decoding the mechanisms behind second primary cancers
Zeng, M., Lin, A., Jiang, A., Qiu, Z., Zhang, H., Chen, S., Xu, M., Liu, Z., Cheng, Q., Zhang, J., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06151-9 · Cited by 21
Cross Talk between COVID-19 and Breast Cancer
Parmar, H. S., Nayak, A., Gavel, P. K., Jha, H. C., Bhagwat, S., & Sharma, R. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009621666210216102236 · Cited by 21
Effects of intravaginal dehydroepiandrosterone on vaginal histomorphology, sex steroid receptor expression and cell proliferation in the rat
Berger, L., Elalfy, M., & Labrie, F. (2007) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2007.09.023 · Cited by 21
Estrogenic activity of furanocoumarins isolated fromAngelica dahurica
Piao, X. L., Yoo, H. H., Kim, H. Y., Kang, T. L., Hwang, G. S., & Park, J. H. (2006) · Archives of Pharmacal Research · doi:10.1007/bf02974073 · Cited by 21
Phytoestrogen α-Zearalanol Antagonizes Homocysteine-Induced Imbalance of Nitric Oxide/Endothelin-1 and Apoptosis in Human Umbilical Vein Endothelial Cells
Duan, J., Dai, S., Fang, C. X., Sun, R., Shaik, S., SHARMA, S. K., Ebadi, M., & Ren, J. T. (2006) · Cell Biochemistry and Biophysics · doi:10.1385/cbb:45:2:137 · Cited by 21
Pharmacoepidemiology
Garbe, E., & Suissa, S. (2013) · Springer eBooks · doi:10.1007/978-0-387-09834-0_31 · Cited by 22
Hormone replacement therapy and nonhormonal control of menopausal symptoms in breast cancer survivors
Cobleigh, M. (1998) · Cancer treatment and research · doi:10.1007/978-1-4615-6189-7_12 · Cited by 21
Primary Prevention of Postmenopausal Osteoporosis
Levinson, W. S. (1998) · JAMA · doi:10.1001/jama.280.21.1821 · Cited by 21
Selective estrogen receptor modulators—A new age of estrogens in cardiovascular disease?
Guzzo, J. A. (2000) · Clinical Cardiology · doi:10.1002/clc.4960230104 · Cited by 21
HORMONE REPLACEMENT THERAPY AND RISK FOR BREAST CANCER
Brinton, L. A. (1997) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70252-8 · Cited by 21
Menopause and sexuality: Ageism and sexism unite.
Rostosky, S. S., & Travis, C. B. (2004) · American Psychological Association eBooks · doi:10.1037/10345-008 · Cited by 21
Hormone replacement therapy after cancers
Creasman, W. T. (2005) · Current Opinion in Internal Medicine · doi:10.1097/01.cco.0000174034.62032.08 · Cited by 21
Patient attitudes to commonly promoted medical interventions
Fitzgerald, S. P., & Phillipov, G. (2000) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2000.tb123869.x · Cited by 21
Beliefs about Breast Cancer Risk and Use of Postmenopausal Hormone Replacement Therapy
Armstrong, K., Popik, S., Guerra, C. E., & Ubel, P. A. (2000) · Medical Decision Making · doi:10.1177/0272989x0002000307 · Cited by 21
Anti-oestrogenic chemoprevention of breast cancer—the need to progress
Powles, T. J. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00771-2 · Cited by 21
“Use of oral contraceptives + [41]”
Gynecologists' trends and attitudes toward prescribing hormone replacement therapy during menopause
Kaplan, B., Aschkenazi-Steinberg, S. O., Yogev, Y., Nahum, R., Sulkes, J., & Phisher, M. (2002) · Menopause The Journal of The North American Menopause Society · doi:10.1097/00042192-200209000-00008 · Cited by 21
Prevention of estrogen carcinogenesis in the hamster kidney by ethinylestradiol: some unique properties of a synthetic estrogen
Li, J. (1998) · Carcinogenesis · doi:10.1093/carcin/19.3.471 · Cited by 21
Is a Dense Mammographic Parenchymal Pattern a Contraindication to Hormonal Replacement Therapy?
Salminen, I. E. S. T. M. (2000) · Acta Oncologica · doi:10.1080/02841860050215954 · Cited by 21
Hormone replacement treatment and breast cancer risk: an age-specific analysis.
Tavani, A., Braga, C., Vecchia, C. L., Negri, E., & Franceschi, S. (1997) · PubMed · Cited by 21
Segmentation of Breast Regions in Mammogram Based on Density: A ReviewPreprint
Saidin, N., Sakim, H. A. M., Ngah, U. K., & Shuaib, I. L. (2012) · arXiv (Cornell University) · doi:10.48550/arxiv.1209.5494 · Cited by 21
Combined Hormone Therapy and Breast Cancer
Gann, P. H., & Morrow, M. (2003) · JAMA · doi:10.1001/jama.289.24.3304 · Cited by 21
Breast cancer and hormonal supplements in postmenopausal women
McPherson, K. (1995) · BMJ · doi:10.1136/bmj.311.7007.699 · Cited by 21
Ortho-silicic Acid Inhibits RANKL-Induced Osteoclastogenesis and Reverses Ovariectomy-Induced Bone Loss In Vivo
Ma, W., Wang, F., You, Y., Wu, W., Chi, H., Jiao, G., Zhang, L., Zhou, H., Wang, H., & Chen, Y. (2020) · Biological Trace Element Research · doi:10.1007/s12011-020-02286-6 · Cited by 20
Current Breast Imaging Modalities, Advances, and Impact on Breast Care
Garcia, E. M., Storm, E. S., Atkinson, L., Kenny, E., & Mitchell, L. S. (2013) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2013.05.002 · Cited by 20
Hormone Replacement Therapy Increases the Risk of Breast Cancera
Colditz, G. A. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb48598.x · Cited by 20
“counts for a small fraction of all cases of breast and (3) personal”
Background
Comparative Safety of Bone Remodeling Agents with a Focus on Osteoporosis Therapies
Kleerekoper, M., & Schein, J. R. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010050 · Cited by 20
“Among women taking estrogen alone or with progestin, evidence exists that the relative risk of developing breast cancer increases with age and duration of use.(35,36) According to the findings of Colditz et al, women who were older than age 55 and who had used HRT for 5 years or more had the most pronounced increased…”
MethodResult
Pregnancy after breast cancer. The relationship of pregnancy to breast cancer development and progression
Surbone, A., & Petrek, J. A. (1998) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(97)10038-5 · Cited by 20
“The use of estrogen replacement therapy after menopause has also been associated with a small increase in breast cancer risk [25–27].”
Background
Hormone Replacement Therapy in Epidemiologic Studies and Randomized Clinical Trials— Are We Checkmate?
Michels, K. B. (2003) · Epidemiology · doi:10.1097/00001648-200301000-00003 · Cited by 20
Incidence of cardiovascular disease, cancer and death in postmenopausal women affirming use of hormone replacement therapy
Hedblad, B., Merlo, J., Manjer, J., Engström, G., Berglund, G. L., & Janzon, L. (2002) · Scandinavian Journal of Public Health · doi:10.1080/140349401753481538 · Cited by 20
7 Hormone replacement therapy
Compston, J. E. (1997) · Baillière s Clinical Rheumatology · doi:10.1016/s0950-3579(97)80021-0 · Cited by 20
Hormone replacement therapy and breast cancer morbidity, mortality and recurrence
Kenemans, P., Scheele, F., & Burger, C. W. (1997) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/s0301-2115(96)02635-8 · Cited by 20
Midlife women making hormone therapy decisions
MacLaren, A., & Woods, N. F. (2001) · Women s Health Issues · doi:10.1016/s1049-3867(01)00082-2 · Cited by 20
Discussion
Nawaz, H., & Katz, D. L. (1999) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(99)00072-0 · Cited by 20
17α-Dihydroequilenin increases hippocampal dendritic spine density of ovariectomized rats
Washburn, S. A., Lewis, C. E., Johnson, J. E., Voytko, M. L., & Shively, C. A. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00303-x · Cited by 20
Hormone Replacement Therapy in the Aged
Jacobs, S., & Hillard, T. (1996) · Drugs & Aging · doi:10.2165/00002512-199608030-00005 · Cited by 20
Treatment of Hyperlipidemia in Women
WENGER, N. K. (1996) · Medical science symposia series · doi:10.1007/978-94-009-0311-1_49 · Cited by 20
Mining Cancer-Specific Disease Comorbidities from a Large Observational Health Database
Chen, Y., & Xu, R. (2014) · Cancer Informatics · doi:10.4137/cin.s13893 · Cited by 17
Quantitative detection of 4-hydroxyequilenin-DNA adducts in mammalian cells using an immunoassay with a novel monoclonal antibody
Okahashi, Y., Iwamoto, T., Suzuki, N., Shibutani, S., Sugiura, S., Itoh, S., Nishiwaki, T., Ueno, S., & Mori, T. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq233 · Cited by 19
Menopause and treatments
Ringa, V. (2000) · Quality of Life Research · doi:10.1023/a:1008913605129 · Cited by 20
Hormone replacement therapy and breast cancer: estimate of risk
Coombs, N. J., Taylor, R. J., Wilcken, N. R. C., & Boyages, J. (2005) · BMJ · doi:10.1136/bmj.331.7512.347 · Cited by 19
The management of familial breast cancer
Bennett, I., Gattas, M. R., & Teh, B. T. (2000) · The Breast · doi:10.1054/brst.2000.0208 · Cited by 19
Progesterone modulates estradiol actions: acute effects at physiological concentrations
Teoh, H., & Man, R. Y. K. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00438-0 · Cited by 19
Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer
Reding, K. W., Doody, D. R., McTiernan, A., Hsu, L., Davis, S., Daling, J. R., Porter, P. L., & Malone, K. E. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1174-7 · Cited by 19
“These findings are consistent with the majority of previous studies reporting a reduction in risk of BCM associated with pre-diagnostic EPT use [5, 7, 9, 18, 25, 26, 30, 34].”
A New Series of Estrogen Receptor Modulators: Effect of Alkyl Substituents on Receptor-Binding Affinity
Kamada, A., Sasaki, A., Kitazawa, N., Okabe, T., Nara, K., Hamaoka, S., Araki, S., & Hagiwara, H. (2004) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.52.79 · Cited by 19
Media Coverage of Women's Health Issues: Is There a Bias in the Reporting of an Association between Hormone Replacement Therapy and Breast Cancer?
Whiteman, M. K., Cui, Y. A., Flaws, J. A., LANGENBERG, P. W., & Bush, T. L. (2001) · Journal of Women s Health & Gender-Based Medicine · doi:10.1089/15246090152543157 · Cited by 19
Developmental effects of ethinylestradiol on reproductive organs of female mice.
Kirigaya, A., Hayashi, S., Iguchi, T., & Sato, T. (2006) · PubMed · Cited by 19
Effect of Halogenated Substituents on the Metabolism and Estrogenic Effects of the Equine Estrogen, Equilenin
Liu, X., Zhang, F., Liu, H., Burdette, J. E., Li, Y., Overk, C., Pisha, E., Yao, J., van Breemen, R. B., Swanson, S. M., et al. (2003) · Chemical Research in Toxicology · doi:10.1021/tx030001f · Cited by 19
Changes of the prescription of hormone therapy in menopausal women: An observational study in Taiwan
Huang, W.-F., Tsai, Y., Hsiao, F., & Liu, W. (2007) · BMC Public Health · doi:10.1186/1471-2458-7-56 · Cited by 19
“Evidence on the potential risks and benefits of combined estrogen/progestin has slowly accumulated and has suggested that the combination of the two acts differently than estrogen alone [2-4].”
Background
Physicians’ views and practices concerning menopausal hormone therapy
Sangi‐Haghpeykar, H., & Poindexter, A. N. (2006) · Maturitas · doi:10.1016/j.maturitas.2006.05.003 · Cited by 19
Selective Estrogen Receptor Modulator Effects on Serum Lipoproteins and Vascular Function in Postmenopausal Women and in Hypercholesterolemic Men
Blum, A., & Cannon, R. O. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb04016.x · Cited by 19
Mutagenic events induced by 4-hydroxyequilin in supF shuttle vector plasmid propagated in human cells
Yasui, M. (2003) · Carcinogenesis · doi:10.1093/carcin/bgg029 · Cited by 19
Pitfalls of the WHIs
Mastorakos, G. P., Sakkas, E. G., Xydakis, A. M., & Creatsas, G. C. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1365.030 · Cited by 19
The Impact of Estrogen Replacement Therapy and Raloxifene on Osteoporosis, Cardiovascular Disease, and Gynecologic Cancers
Umland, E. M., Rinaldi, C., Parks, S. M., & Boyce, E. G. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.18463 · Cited by 19

Authors: Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., & Speizer, F. E.
Affiliations: Brigham and Women's Hospital (US)
ORCID: Colditz, Graham A.
Hankinson, Susan E.
Willett, Walter C.
Manson, JoAnn E.
Stampfer, Meir J.
Hennekens, Charles
Rosner, Bernard
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1995-06-15
Volume: 332
Issue: 24
Pages: 1589-1593
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199506153322401
OpenAlex: W2607238143
Cited by: 1,487
References: 32
Citations by year: 2026: 5 · 2025: 4 · 2024: 6 · 2023: 8 · 2022: 8 · 2021: 13 · 2020: 13 · 2019: 11 · 2018: 17 · 2017: 16 · 2016: 16 · 2015: 18 · 2014: 21 · 2013: 18 · 2012: 26
FWCI: 111.38
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (CA 40956)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Health Sciences › Medicine › Oncology › Cancer Risks and Factors
Keywords: breast cancer risk, hormone replacement therapy, estrogen therapy, progestins, estrogen plus progestin, duration of hormone use, age-related risk, breast cancer mortality, Nurses' Health Study
MeSH terms: Aged, Breast Neoplasms, Estrogens, Female, Follow-Up Studies, Humans, Middle Aged, Progestins, Prospective Studies, Risk, Risk Factors, Cohort Studies, Estrogen Replacement Therapy, Confidence Intervals, Case-Control Studies, Postmenopause

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks